Trial · NCT02493426

Single Dose Intranasal Oxytocin and Cognitive Effects in Autism

NCT02493426, Phase 2, Completed, University of Minnesota; results first posted 2023-01-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Single Dose Intranasal Oxytocin and Cognitive Effects in Autism. Trials, record NCT02493426. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02493426

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Single Dose Intranasal Oxytocin and Cognitive Effects in Autism
NCT number: NCT02493426
Status: Completed
Phases: Phase 2
Enrollment: 27 participants, actual
Lead sponsor: University of Minnesota
Conditions: Autism Spectrum Disorders
Interventions: Intranasal Oxytocin, Placebo
First posted: 2015-07-09
Last updated: 2023-01-23
Results first posted: 2023-01-23

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Reading the Mind in the Eyes Task (RMET)	2 weeks	Social Cognition Task-- We are reporting raw score (# of correct responses) Minimum value is 0 and maximum value is 28. A higher score means better performance / outcome.
Primary	Rapid Automatized Naming (RAN)	2 weeks	Cognitive Rigidity Task for \>10 years old-- Time to name attribute of stimulus requested; minimum time is 0, there is no maximum time. Lower score is better.
Primary	Dynamic Affect Recognition Evaluation (DARE)	2 weeks	Task Performance with Physiological Data. We reported the raw score - total number correct. Minimum is 0, maximum is 12. Higher score means better performance / outcome.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Reading the Mind in the Eyes Task (RMET)	2 weeks	total raw score	MEAN
PRIMARY	Rapid Automatized Naming (RAN)	2 weeks	naming time (seconds)	MEAN
PRIMARY	Dynamic Affect Recognition Evaluation (DARE)	2 weeks	total raw score	MEAN

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Reading the Mind in the Eyes Task (RMET)	Placebo Then Oxytocin	Intervention Period 1	18.07	Standard Deviation 4.48	total raw score
Reading the Mind in the Eyes Task (RMET)	Intranasal Oxytocin Then Placebo	Intervention Period 1	18.08	Standard Deviation 2.47	total raw score
Reading the Mind in the Eyes Task (RMET)	Placebo Then Oxytocin	Intervention Period 2	17.86	Standard Deviation 4.77	total raw score
Reading the Mind in the Eyes Task (RMET)	Intranasal Oxytocin Then Placebo	Intervention Period 2	18.09	Standard Deviation 3.08	total raw score
Rapid Automatized Naming (RAN)	Placebo Then Oxytocin	Symbolic: Intervention Period 1	18.08	Standard Deviation 4.69	naming time (seconds)
Rapid Automatized Naming (RAN)	Intranasal Oxytocin Then Placebo	Symbolic: Intervention Period 1	16.13	Standard Deviation 6.21	naming time (seconds)
Rapid Automatized Naming (RAN)	Placebo Then Oxytocin	Symbolic: Intervention Period 2	17.98	Standard Deviation 5.71	naming time (seconds)
Rapid Automatized Naming (RAN)	Intranasal Oxytocin Then Placebo	Symbolic: Intervention Period 2	15.28	Standard Deviation 4.63	naming time (seconds)
Rapid Automatized Naming (RAN)	Placebo Then Oxytocin	Non-symbolic: Intervention Period 1	27.93	Standard Deviation 6.02	naming time (seconds)
Rapid Automatized Naming (RAN)	Intranasal Oxytocin Then Placebo	Non-symbolic: Intervention Period 1	24.13	Standard Deviation 6.31	naming time (seconds)

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo Then Intranasal Oxytocin	14
Overall Study	STARTED	Intranasal Oxytocin Then Placebo	13
Overall Study	COMPLETED	Placebo Then Intranasal Oxytocin	14
Overall Study	COMPLETED	Intranasal Oxytocin Then Placebo	12
Overall Study	NOT COMPLETED	Placebo Then Intranasal Oxytocin	0
Overall Study	NOT COMPLETED	Intranasal Oxytocin Then Placebo	1

Source ClinicalTrials.gov

Adverse events36

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	General disorders	Placebo	0	27	0
other	Headache	General disorders	Intranasal Oxytocin	1	27	1
other	Bloody nose	Injury, poisoning and procedural complications	Placebo	0	27	0
other	Bloody nose	Injury, poisoning and procedural complications	Intranasal Oxytocin	1	27	1
other	Fatigue	General disorders	Placebo	1	27	1
other	Fatigue	General disorders	Intranasal Oxytocin	1	27	1
other	Mouth pain	Injury, poisoning and procedural complications	Placebo	0	27	0
other	Mouth pain	Injury, poisoning and procedural complications	Intranasal Oxytocin	1	27	1
other	Greater awakeness	General disorders	Placebo	0	27	0
other	Greater awakeness	General disorders	Intranasal Oxytocin	1	27	1

1 to 10 of 36Source ClinicalTrials.gov

See all 36 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	27
Total, all-cause mortality	Intranasal Oxytocin	0	27
Total, other adverse events	Placebo	14	27
Total, other adverse events	Intranasal Oxytocin	13	27
Total, serious adverse events	Placebo	0	27
Total, serious adverse events	Intranasal Oxytocin	0	27

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Intranasal Oxytocin vs Placebo: deaths from any cause	Trial comparisons
Intranasal Oxytocin vs Placebo: serious adverse events	Trial comparisons

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as
Serial Naming Task	Primary outcome

Source ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02493426

GET https://conductscience.org/api/trials/v1/NCT02493426/events?page=2

API reference For AI assistants